As of 2026-05-26, the Intrinsic Value of YiChang HEC ChangJiang Pharmaceutical Co Ltd (1558.HK) is 11.08 HKD. This 1558.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 15.88 HKD, the upside of YiChang HEC ChangJiang Pharmaceutical Co Ltd is -30.20%.
The range of the Intrinsic Value is 6.14 - 31.47 HKD
Based on its market price of 15.88 HKD and our intrinsic valuation, YiChang HEC ChangJiang Pharmaceutical Co Ltd (1558.HK) is overvalued by 30.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 6.14 - 31.47 | 11.08 | -30.2% |
| DCF (Growth 10y) | 10.12 - 46.01 | 17.19 | 8.2% |
| DCF (EBITDA 5y) | 36.03 - 59.85 | 47.47 | 198.9% |
| DCF (EBITDA 10y) | 31.64 - 60.31 | 44.47 | 180.0% |
| Fair Value | 15.81 - 15.81 | 15.81 | -0.46% |
| P/E | 13.92 - 27.23 | 17.26 | 8.7% |
| EV/EBITDA | 10.79 - 27.83 | 18.04 | 13.6% |
| EPV | 6.67 - 11.62 | 9.15 | -42.4% |
| DDM - Stable | 5.14 - 24.99 | 15.06 | -5.2% |
| DDM - Multi | 9.54 - 38.55 | 15.58 | -1.9% |
| Market Cap (mil) | 13,973.92 |
| Beta | 0.31 |
| Outstanding shares (mil) | 879.97 |
| Enterprise Value (mil) | 14,931.83 |
| Market risk premium | 5.98% |
| Cost of Equity | 8.45% |
| Cost of Debt | 4.25% |
| WACC | 7.69% |